1
|
Koyama K, Ishikawa H, Abe M, Shiose Y, Ueno S, Qiu Y, Nakamaru K, Murakami M. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One 2022; 17:e0267027. [PMID: 35503762 PMCID: PMC9064083 DOI: 10.1371/journal.pone.0267027] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Accepted: 04/01/2022] [Indexed: 11/23/2022] Open
Abstract
ErbB3 (HER3), a member of the HER family, is overexpressed in various cancers and plays an important role in cell proliferation and survival. Certain HER3 mutations have also been identified as oncogenic drivers, making them potential therapeutic targets. In the current study, antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3 directed antibody drug conjugate, was evaluated in tumor models with clinically reported HER3 mutations. MDA-MB-231, a HER3-negative human triple-negative breast cancer cell line, was transduced with lentiviral vectors encoding HER3 wild type (HER3WT), one of 11 HER3 mutations, or HER3 empty vector (HER3EV), in the presence/absence of HER2 overexpression. Targeted delivery of HER3-DXd was assessed using cell-surface binding, lysosomal trafficking, and cell-growth inhibition assays. HER3-DXd bound to the surface of HER3WT and mutant cells in a similar, concentration-dependent manner but not to HER3EV. HER3-DXd was translocated to the lysosome, where time- and concentration-dependent signals were observed in the HER3 mutant and HER3WT cells. HER3-DXd inhibited the growth of HER3WT and HER3 mutant cells. HER3-DXd activity was observed in the presence and absence of HER2 overexpression. These data suggest that HER3-DXd may have activity against tumors expressing wild type HER3 or clinically observed HER3 mutations, supporting further clinical evaluation.
Collapse
Affiliation(s)
- Kumiko Koyama
- Translational Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan
- * E-mail:
| | - Hirokazu Ishikawa
- Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan
| | - Manabu Abe
- Specialty Medicine Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan
| | - Yoshinobu Shiose
- Translational Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan
| | - Suguru Ueno
- Cell Therapy Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan
| | - Yang Qiu
- Daiichi Sankyo, Inc., Basking Ridge, NJ, United States of America
| | - Kenji Nakamaru
- Translational Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan
| | - Masato Murakami
- Daiichi Sankyo, Inc., Basking Ridge, NJ, United States of America
| |
Collapse
|
2
|
Koyama K, Ishikawa H, Abe M, Shiose Y, Ueno S, Nakamaru K, Murakami M. Abstract 5201: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits in vitro antitumor activity against breast cancer cells expressing HER3 mutations without dependence on HER2 overexpression. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5201] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: U3-1402, a novel HER3-targeting antibody-drug conjugate (ADC) composed of a fully human anti-HER3 antibody (patritumab), tetrapeptide-based linker, and topoisomerase I inhibitor payload, is currently being studied in clinical trials for patients with HER3-positive breast cancer (phase 1/2, NCT02980341) and NSCLC (phase 1, NCT03260491). HER3 is overexpressed in multiple human cancers and plays an important role in cell proliferation and survival. Furthermore, HER3 somatic mutations have been reported in several cancers, including breast cancer, and certain HER3 mutants demonstrates oncogenic activity in the presence or absence of HER2 overexpression. Here, we evaluate if U3-1402 shows an antitumor activity against clinically reported HER3 mutations as observed with HER3 wild-type (HER3WT).
Methods: MDA-MB-231, a triple negative breast cancer cell line (HER3-negative), was transduced with lentiviral vectors encoding flag-tagged HER3WT or 11 HER3 mutations (V104L, V104M, A232V, P262H, G284R, D297Y, G325R, T355I, Q809R, S846I, and E928G), along with HER3 empty vector (HER3EV), in the presence and absence of HER2 overexpression. To assess the targeted delivery of U3-1402 to the HER3 transfectants, we studied cell surface binding of U3-1402 (0.1–100 nM) using flow cytometry, and assessed lysosomal trafficking of U3-1402 (0.1–10 nM) using high-content imaging system with utilizing pH-sensitive pHrodo iFL conjugated antibody. Cell growth inhibition activity of U3-1402 was also evaluated.
Results: U3-1402 bound to HER3WT cell surface in a concentration-dependent manner, but not to HER3EV cell surface. Each of the above HER3 mutant cells demonstrated the same cell surface binding property of U3-1402 as HER3WT cells. Subsequently, U3-1402 was translocated to the lysosome, where pHrodo-labeled U3-1402-derived signals were observed in time- and concentration-dependent manners in any of the HER3 mutant cells, at comparable levels to those in the HER3WT cells. Cell growth inhibition activity of U3-1402 was observed in both HER3WT cells and all HER3 mutant cells tested. HER2 overexpression had no significant impact on cell surface binding, trafficking and cell growth inhibition activity of U3-1402.
Conclusion: U3-1402 has a potential to show antitumor activity against HER3 mutant cells with the same potency as HER3WT cells, regardless of HER2 overexpression. This finding provides insights into HER3-targeted therapy, in which an efficient payload delivery via ADC-mediated internalization could be achieved for HER3 mutations.
Citation Format: Kumiko Koyama, Hirokazu Ishikawa, Manabu Abe, Yoshinobu Shiose, Suguru Ueno, Kenji Nakamaru, Masato Murakami. U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits in vitro antitumor activity against breast cancer cells expressing HER3 mutations without dependence on HER2 overexpression [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5201.
Collapse
|
3
|
Papadopoulos KP, Gandhi L, Janne PA, Ou SHI, Shaw A, Goldberg TR, Greenberg J, Gu X, Tachibana M, Senaldi G, Shiga R, Zahir H, Nakamaru K, Borazanci E. First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.2514] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Leena Gandhi
- New York University Perlmutter Cancer Center, New York, NY
| | | | | | - Alice Shaw
- Massachusetts General Hospital, Boston, MA
| | | | | | - Xuemin Gu
- Daiichi Sankyo, Inc., Basking Ridge, NJ
| | | | | | | | | | | | - Erkut Borazanci
- HonorHealth and Translational Genomics Research Institute, Scottsdale, AZ
| |
Collapse
|
4
|
Fujiwara Y, Takeda M, Yamamoto N, Nakagawa K, Nosaki K, Toyozawa R, Abe C, Shiga R, Nakamaru K, Seto T. Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget 2018; 9:23729-23737. [PMID: 29805770 PMCID: PMC5955103 DOI: 10.18632/oncotarget.25263] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Accepted: 04/06/2018] [Indexed: 11/25/2022] Open
Abstract
Oncogenic ROS1 and NTRK fusions were reported in solid tumors, including non-small cell lung cancer (NSCLC). DS-6051b is an oral, potent selective small molecule tyrosine kinase inhibitor. We report the safety, tolerability, efficacy, and pharmacokinetics of DS-6051b in 15 Japanese patients with NSCLC harboring ROS1 fusions. Patients received DS-6051b once daily (400 mg n = 6; 600 mg n = 6; or 800 mg n = 3) for cycles of 3 weeks. Safety, tolerability, maximum-tolerated dose, pharmacokinetics, and recommended dose for phase II were determined. Common treatment-related adverse events were increased: aspartate aminotransferase and alanine aminotransferase (80.0% each), diarrhea (53.3%), and nausea (46.7%). Dose-limiting toxicities (two grade-3 alanine aminotransferase increases) were seen in the 800 mg cohort. The maximum-tolerated dose and recommended phase II dose was 600 mg once daily. Plasma concentrations of free DS-6051b and DS-6051a increased with dose. Compared with a US phase I study, AUC0-24 h on day 15 was higher but narrowed after body weight correction. Objective response rate was 58.3% in patients with target lesions (n = 12) and 66.7% in crizotinib-naïve patients (n = 9). Disease control rate was 100%. DS-6051b is well tolerated and effective in Japanese patients with NSCLC harboring ROS1 fusions and might be a targeted therapy for advanced NSCLC.
Collapse
Affiliation(s)
- Yutaka Fujiwara
- Department of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan
| | - Masayuki Takeda
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama-shi, Osaka 589-8511, Japan
| | - Noboru Yamamoto
- Department of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan
| | - Kazuhiko Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama-shi, Osaka 589-8511, Japan
| | - Kaname Nosaki
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Minami-ku, Fukuoka-shi, Fukuoka 811-1395, Japan
| | - Ryo Toyozawa
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Minami-ku, Fukuoka-shi, Fukuoka 811-1395, Japan
| | - Chihiro Abe
- Daiichi Sankyo Co., Ltd., Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Ryota Shiga
- Daiichi Sankyo Co., Ltd., Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Kenji Nakamaru
- Daiichi Sankyo Co., Ltd., Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Minami-ku, Fukuoka-shi, Fukuoka 811-1395, Japan
| |
Collapse
|
5
|
Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 2018; 78:2721-2731. [PMID: 29490944 DOI: 10.1158/0008-5472.can-17-0949] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Revised: 12/05/2017] [Accepted: 02/22/2018] [Indexed: 12/21/2022]
Abstract
Early clinical trials using murine double minute 2 (MDM2) inhibitors demonstrated proof-of-concept of p53-induced apoptosis by MDM2 inhibition in cancer cells; however, not all wild-type TP53 tumors are sensitive to MDM2 inhibition. Therefore, more potent inhibitors and biomarkers predictive of tumor sensitivity are needed. The novel MDM2 inhibitor DS-3032b is 10-fold more potent than the first-generation inhibitor nutlin-3a. TP53 mutations were predictive of resistance to DS-3032b, and allele frequencies of TP53 mutations were negatively correlated with sensitivity to DS-3032b. However, sensitivity to DS-3032b of TP53 wild-type tumors varied greatly. We thus used two methods to create predictive gene signatures. First, by comparing sensitivity to MDM2 inhibition with basal mRNA expression profiles in 240 cancer cell lines, a 175-gene signature was defined and validated in patient-derived tumor xenograft models and ex vivo human acute myeloid leukemia (AML) cells. Second, an AML-specific 1,532-gene signature was defined by performing random forest analysis with cross-validation using gene expression profiles of 41 primary AML samples. The combination of TP53 mutation status with the two gene signatures provided the best positive predictive values (81% and 82%, compared with 62% for TP53 mutation status alone). In addition, the top-ranked 50 genes selected from the AML-specific 1,532-gene signature conserved high predictive performance, suggesting that a more feasible size of gene signature can be generated through this method for clinical implementation. Our model is being tested in ongoing clinical trials of MDM2 inhibitors.Significance: This study demonstrates that gene expression profiling combined with TP53 mutational status predicts antitumor effects of MDM2 inhibitors in vitro and in vivoCancer Res; 78(10); 2721-31. ©2018 AACR.
Collapse
Affiliation(s)
- Jo Ishizawa
- Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Kenji Nakamaru
- Daiichi Sankyo Co., Ltd., Hiromachi, Shinagawa-ku, Tokyo, Japan
| | - Takahiko Seki
- Daiichi Sankyo Co., Ltd., Hiromachi, Shinagawa-ku, Tokyo, Japan
| | - Koichi Tazaki
- Daiichi Sankyo Co., Ltd., Hiromachi, Shinagawa-ku, Tokyo, Japan
| | - Kensuke Kojima
- Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.,Hematology, Respiratory Medicine and Oncology, Department of Medicine, Saga University, Saga, Japan
| | - Dhruv Chachad
- Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Ran Zhao
- Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Lauren Heese
- Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Wencai Ma
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Man Chun John Ma
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Courtney DiNardo
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Sherry Pierce
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Keyur P Patel
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Archie Tse
- Daiichi Sankyo, Inc., Edison, New Jersey
| | - R Eric Davis
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Arvind Rao
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Michael Andreeff
- Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
| |
Collapse
|
6
|
Kristof J, Sakrison K, Jin X, Nakamaru K, Schneider M, Beckman RA, Freeman D, Spittle C, Feng W. Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue. Biomark Insights 2017; 12:1177271917699850. [PMID: 28469400 PMCID: PMC5391987 DOI: 10.1177/1177271917699850] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2016] [Accepted: 02/13/2017] [Indexed: 11/17/2022] Open
Abstract
In preclinical studies, heregulin (HRG) expression was shown to be the most relevant predictive biomarker for response to patritumab, a fully human anti–epidermal growth factor receptor 3 monoclonal antibody. In support of a phase 2 study of erlotinib ± patritumab in non–small cell lung cancer (NSCLC), a reverse-transcription quantitative polymerase chain reaction (RT-qPCR) assay for relative quantification of HRG expression from formalin-fixed paraffin-embedded (FFPE) NSCLC tissue samples was developed and validated and described herein. Test specimens included matched FFPE normal lung and NSCLC and frozen NSCLC tissue, and HRG-positive and HRG-negative cell lines. Formalin-fixed paraffin-embedded tissue was examined for functional performance. Heregulin distribution was also analyzed across 200 NSCLC commercial samples. Applied Biosystems TaqMan Gene Expression Assays were run on the Bio-Rad CFX96 real-time PCR platform. Heregulin RT-qPCR assay specificity, PCR efficiency, PCR linearity, and reproducibility were demonstrated. The final assay parameters included the Qiagen FFPE RNA Extraction Kit for RNA extraction from FFPE NSCLC tissue, 50 ng of RNA input, and 3 reference (housekeeping) genes (HMBS, IPO8, and EIF2B1), which had expression levels similar to HRG expression levels and were stable among FFPE NSCLC samples. Using the validated assay, unimodal HRG distribution was confirmed across 185 evaluable FFPE NSCLC commercial samples. Feasibility of an RT-qPCR assay for the quantification of HRG expression in FFPE NSCLC specimens was demonstrated.
Collapse
Affiliation(s)
- Jessica Kristof
- Clinical Assay Development, MolecularMD, Portland, OR, USA.,Phylos Bioscience, Portland, OR, USA
| | - Kellen Sakrison
- Clinical Assay Development, MolecularMD, Portland, OR, USA.,ARUP Laboratories, Salt Lake City, UT, USA
| | - Xiaoping Jin
- Biostatistics and Data Management, Daiichi Sankyo Pharma Development, Edison, NJ, USA.,MedImmune, Gaithersburg, MD, USA
| | - Kenji Nakamaru
- Translational Medicine and Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan
| | | | - Robert A Beckman
- Departments of Oncology and of Biostatistics, Bioinformatics & Biomathematics, Georgetown Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Georgetown University, Washington, DC, USA
| | - Daniel Freeman
- MedImmune, Gaithersburg, MD, USA.,Translational Medicine and Clinical Pharmacology, Daiichi Sankyo Pharma Development, Edison, NJ, USA
| | - Cindy Spittle
- Clinical Assay Development, MolecularMD, Portland, OR, USA
| | - Wenqin Feng
- Translational Medicine and Clinical Pharmacology, Daiichi Sankyo Pharma Development, Edison, NJ, USA
| |
Collapse
|
7
|
Nosaki K, Fujiwara Y, Takeda M, Yamamoto N, Nakagawa K, Abe C, Shiga R, Nakamaru K, Seto T. P2.06-002 Phase I Study of DS-6051b, a ROS1/NTRK Inhibitor, in Japanese Subjects with Advanced Solid Tumors Harboring Either a ROS1 or NTRK Fusion Gene. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1495] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Yeh I, Tee MK, Botton T, Shain AH, Sparatta AJ, Gagnon A, Vemula SS, Garrido MC, Nakamaru K, Isoyama T, McCalmont TH, LeBoit PE, Bastian BC. NTRK3 kinase fusions in Spitz tumours. J Pathol 2016; 240:282-290. [PMID: 27477320 PMCID: PMC5071153 DOI: 10.1002/path.4775] [Citation(s) in RCA: 107] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Revised: 07/01/2016] [Accepted: 07/21/2016] [Indexed: 12/18/2022]
Abstract
Oncogenic fusions in TRK family receptor tyrosine kinases have been identified in several cancers and can serve as therapeutic targets. We identified ETV6-NTRK3, MYO5A-NTRK3 and MYH9-NTRK3 fusions in Spitz tumours, and demonstrated that NTRK3 fusions constitutively activate the mitogen-activated protein kinase, phosphoinositide 3-kinase and phospholipase Cγ1 pathways in melanocytes. This signalling was inhibited by DS-6051a, a small-molecule inhibitor of NTRK1/2/3 and ROS1. NTRK3 fusions expand the range of oncogenic kinase fusions in melanocytic neoplasms and offer targets for a small subset of melanomas for which no targeted options currently exist. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Iwei Yeh
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.
- Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
| | - Meng Kian Tee
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
| | - Thomas Botton
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
| | - A Hunter Shain
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
| | - Alyssa J Sparatta
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
| | - Alexander Gagnon
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
- Department of Pathology, University of California San Francisco, San Francisco, CA, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
| | - Swapna S Vemula
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
- Department of Pathology, University of California San Francisco, San Francisco, CA, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
| | - Maria C Garrido
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
| | - Kenji Nakamaru
- Translational Research and Clinical Pharmacology, Daiichi Sankyo, Co., Ltd, Tokyo, Japan
| | - Takeshi Isoyama
- Oncology Laboratories, Daiichi Sankyo, Co., Ltd, Tokyo, Japan
| | - Timothy H McCalmont
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
- Department of Pathology, University of California San Francisco, San Francisco, CA, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
| | - Philip E LeBoit
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
- Department of Pathology, University of California San Francisco, San Francisco, CA, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
| | - Boris C Bastian
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.
- Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
| |
Collapse
|
9
|
Nakamaru K, Seki T, Tazaki K, Tse A. Abstract B5: Preclinical characterization of a novel orally-available MDM2 inhibitor DS-3032b: Anti-tumor profile and predictive biomarkers for sensitivity. Biomarkers 2016. [DOI: 10.1158/1535-7163.targ-15-b5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Tse A, Rao A, Andreeff M. Abstract B1: Gene expression and TP53 mutation analysis predict sensitivity of leukemia cells to MDM2 inhibition by DS-3032b. Mol Cancer Ther 2015. [DOI: 10.1158/1535-7163.targ-15-b1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: MDM2 overexpression, by preventing p53 activation, contributes to the growth and development of a variety of solid tumors and hematologic malignancies; hence, MDM2 inhibition could be a promising novel therapeutic strategy. Several MDM2 inhibitors have shown promise in early clinical trials. While preclinical studies generally reveal a requirement of wild-type (wt) TP53 for activity, tumor response to MDM2 inhibitors varies widely in the clinic and may not be strictly linked to TP53 mutational status. Identification of predictive biomarkers is therefore needed to enrich for patients with high likelihood of response. We here propose two gene signature-based models to predict the sensitivity of AML cells to MDM2 inhibition using two different methods.
Methods: Leukemia samples isolated from peripheral blood or bone marrow of patients with newly diagnosed or relapsed/refractory AML were treated using DS-3032b (Daiichi-Sankyo), a dispiropyrrolidine-based, highly potent MDM2 inhibitor currently undergoing clinical trials in solid and hematological malignancies. Forty-one primary AML samples were treated ex vivo for 48 hours with DS-3032b (0, 25, 50, 100, 250, 500, and 1000 nM), and live cell numbers were determined. To define drug sensitivity/resistance, area under the curve (AUC) values, based on%live cell number measured at each concentration, were calculated. Baseline whole-genome RNA expression profile (Affymetrix Human Genome U133 Plus 2.0 Array) and TP53 mutation status (next generation sequencing) were determined. In the first model, we validated a predictive 175-gene signature that was established in a wide range of cancer cells by Daiichi Sankyo. In the second model, we used the random forest method with cross validation to establish a new predictive gene signature.
Results: Eight samples (20%) had TP53 mutations. 6/8 (75%) p53 mutant and 8/33 (24%) of p53 wt samples were resistant (p = 0.01).
In the first model, 11 each p53 wt samples were selected as sensitive or resistant to DS-3032 based on AUC values, and the 175-gene signature was applied. The prediction accuracy was 72%. In the genotype mixed samples, 14 each sensitive and resistant samples were selected, and the prediction accuracy was 79%.
In the second model, we focused on 33 p53 wt samples and trichotomize the samples in the same way as in the first model, and investigated the accuracy of gene expression-derived prediction model with (A) 1500 gene set with the highest variance in mRNA expression (unbiased approach), (B) 32 gene set derived from previous studies (referenced approach), (C) combined (A+B) gene set. The sensitivities to predict cases with high drug sensitivity were 72%, 73% and 82% in scenarios (A), (B) and (C), respectively. The analysis was then extended to all 41 samples and the sensitivity to predict cases with high drug sensitivity remained high (64%, 64% and 72%). The results indicate that an unbiased approach can create a prediction model as accurate as the referenced approach, and moreover, that the combining approach can provide the highest prediction of sensitivity to the MDM2 inhibitor.
Conclusion: The two models reported here could provide a novel strategy to identify the optimal gene signatures for predicting the cases most sensitive to MDM2 inhibitors prior to therapy. These models will be tested in an ongoing AML phase 1 clinical study of DS-3032b.
Citation Format: Jo Ishizawa, Kenji Nakamaru, Takahiko Seki, Koichi Tazaki, Kensuke Kojima, Dhruv Chachad, Archie Tse, Arvind Rao, Michael Andreeff. Gene expression and TP53 mutation analysis predict sensitivity of leukemia cells to MDM2 inhibition by DS-3032b. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B1.
Collapse
Affiliation(s)
- Jo Ishizawa
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | - Kensuke Kojima
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Dhruv Chachad
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Arvind Rao
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
11
|
Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, Ruhe J, Bange J, Nakamaru K, Chen S, Tsuchihashi Z, von Pawel J, Copigneaux C, Beckman RA. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. EBioMedicine 2015; 2:264-71. [PMID: 26137564 PMCID: PMC4484825 DOI: 10.1016/j.ebiom.2015.02.005] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Revised: 02/10/2015] [Accepted: 02/11/2015] [Indexed: 12/15/2022] Open
Abstract
Background During early clinical development, prospective identification of a predictive biomarker and validation of an assay method may not always be feasible. Dichotomizing a continuous biomarker measure to classify responders also leads to challenges. We present a case study of a prospective–retrospective approach for a continuous biomarker identified after patient enrollment but defined prospectively before the unblinding of data. An analysis of the strengths and weaknesses of this approach and the challenges encountered in its practical application are also provided. Methods HERALD (NCT02134015) was a double-blind, phase 2 study in patients with non-small cell lung cancer (NSCLC) randomized to erlotinib with placebo or with high or low doses of patritumab, a monoclonal antibody targeted against human epidermal growth factor receptor 3 (HER3). While the primary objective was to assess safety and progression-free survival (PFS), a secondary objective was to determine a single predictive biomarker hypothesis to identify subjects most likely to benefit from the addition of patritumab. Although not identified as the primary biomarker in the study protocol, on the basis of preclinical results from 2 independent laboratories, expression levels of the HER3 ligand heregulin (HRG) were prospectively declared the predictive biomarker before data unblinding but after subject enrollment. An assay to measure HRG mRNA was developed and validated. Other biomarkers, such as epidermal growth factor receptor (EGFR) mutation status, were also evaluated in an exploratory fashion. The cutoff value for high vs. low HRG mRNA levels was set at the median delta threshold cycle. A maximum likelihood analysis was performed to evaluate the provisional cutoff. The relationship of HRG values to PFS hazard ratios (HRs) was assessed as a measure of internal validation. Additional NSCLC samples were analyzed to characterize HRG mRNA distribution. Results The subgroup of patients with high HRG mRNA levels (“HRG-high”) demonstrated clinical benefit from patritumab treatment with HRs of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively. However, only 102 of the 215 randomized patients (47.4%) had sufficient tumor samples for HRG mRNA measurement. Maximum likelihood analysis showed that the provisional cutoff was within the optimal range. In the placebo arm, the HRG-high subgroup demonstrated worse prognosis compared with HRG-low. A continuous relationship was observed between increased HRG mRNA levels and lower HR. Additional NSCLC samples (N = 300) demonstrated a similar unimodal distribution to that observed in this study, suggesting that the defined cutoff may be applicable to future NSCLC studies. Conclusions The prospective–retrospective approach was successful in clinically validating a probable predictive biomarker. Post hoc in vitro studies and statistical analyses permitted further testing of the underlying assumptions. However, limitations of this analysis include the incomplete collection of adequate tumor tissue and a lack of stratification. In a phase 3 study, findings are being confirmed, and the HRG cutoff value is being further refined. ClinicalTrials.gov Number NCT02134015. High heregulin levels predict benefit from patritumab treatment in patients with NSCLC. A prospective–retrospective approach provisionally validated a predictive biomarker. Post hoc analyses can be used to test underlying assumptions in biomarker validation. The median may be a reasonable initial cutoff for a unimodal continuous biomarker.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Neutralizing/administration & dosage
- Antibodies, Neutralizing/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/genetics
- Broadly Neutralizing Antibodies
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Carcinoma, Non-Small-Cell Lung/mortality
- Disease-Free Survival
- Double-Blind Method
- ErbB Receptors/genetics
- Erlotinib Hydrochloride/administration & dosage
- Erlotinib Hydrochloride/therapeutic use
- Female
- Humans
- Lung Neoplasms/drug therapy
- Lung Neoplasms/mortality
- Male
- Middle Aged
- Neuregulin-1/blood
- Neuregulin-1/genetics
- Prospective Studies
- Receptor, ErbB-3/blood
- Receptor, ErbB-3/immunology
- Retrospective Studies
- Translational Research, Biomedical
- Treatment Outcome
Collapse
Affiliation(s)
- Jeanne Mendell
- Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA
- Corresponding author.
| | - Daniel J. Freeman
- Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA
| | - Wenqin Feng
- Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA
| | - Thore Hettmann
- U3 Pharma GmbH, Fraunhoferstraße 22, 82152 Martinsried, Germany
| | | | - Sabine Blum
- U3 Pharma GmbH, Fraunhoferstraße 22, 82152 Martinsried, Germany
| | - Jens Ruhe
- U3 Pharma GmbH, Fraunhoferstraße 22, 82152 Martinsried, Germany
| | - Johannes Bange
- U3 Pharma GmbH, Fraunhoferstraße 22, 82152 Martinsried, Germany
| | - Kenji Nakamaru
- Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Shuquan Chen
- Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA
| | | | - Joachim von Pawel
- Asklepios Fachkliniken, München Gauting, Robert-Koch-Allee 2, 82131 Gauting, Germany
| | | | - Robert A. Beckman
- Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA
| |
Collapse
|
12
|
Mendell-Harary J, Ruhe J, Schneider M, Feng W, Freeman DJ, Nakamaru K, Jin X, Tsuchihashi Z, Von Pawel J, Copigneaux C, Beckman RA. Identification of a predictive biomarker for patritumab (P), an anti-HER3 monoclonal antibody, in advanced NSCLC. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e19016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Jens Ruhe
- U3 Pharma GmbH, Martinsried, Germany
| | | | - Wenqin Feng
- Daiichi Sankyo Pharma Development, Edison, NJ
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Min KD, Asakura M, Liao Y, Nakamaru K, Okazaki H, Takahashi T, Fujimoto K, Ito S, Takahashi A, Asanuma H, Yamazaki S, Minamino T, Sanada S, Seguchi O, Nakano A, Ando Y, Otsuka T, Furukawa H, Isomura T, Takashima S, Mochizuki N, Kitakaze M. Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochem Biophys Res Commun 2010; 393:55-60. [PMID: 20100464 DOI: 10.1016/j.bbrc.2010.01.076] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2010] [Accepted: 01/18/2010] [Indexed: 11/19/2022]
Abstract
Although various management methods have been developed for heart failure, it is necessary to investigate the diagnostic or therapeutic targets of heart failure. Accordingly, we have developed different approaches for managing heart failure by using conventional microarray analyses. We analyzed gene expression profiles of myocardial samples from 12 patients with heart failure and constructed datasets of heart failure-associated genes using clinical parameters such as pulmonary artery pressure (PAP) and ejection fraction (EF). From these 12 genes, we selected four genes with high expression levels in the heart, and examined their novelty by performing a literature-based search. In addition, we included four G-protein-coupled receptor (GPCR)-encoding genes, three enzyme-encoding genes, and one ion-channel protein-encoding gene to identify a drug target for heart failure using in silico microarray database. After the in vitro functional screening using adenovirus transfections of 12 genes into rat cardiomyocytes, we generated gene-targeting mice of five candidate genes, namely, MYLK3, GPR37L1, GPR35, MMP23, and NBC1. The results revealed that systolic blood pressure differed significantly between GPR35-KO and GPR35-WT mice as well as between GPR37L1-Tg and GPR37L1-KO mice. Further, the heart weight/body weight ratio between MYLK3-Tg and MYLK3-WT mice and between GPR37L1-Tg and GPR37L1-KO mice differed significantly. Hence, microarray analysis combined with clinical parameters can be an effective method to identify novel therapeutic targets for the prevention or management of heart failure.
Collapse
|
14
|
Asakura M, Asanuma H, Kim J, Liao Y, Nakamaru K, Fujita M, Komamura K, Isomura T, Furukawa H, Tomoike H, Kitakaze M. Impact of adenosine receptor signaling and metabolism on pathophysiology in patients with chronic heart failure. Hypertens Res 2008; 30:781-7. [PMID: 18037770 DOI: 10.1291/hypres.30.781] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Adenosine is well known to be a cardioprotective substance in ischemic heart disease. However, the modulation of adenosine receptors and the production and degradation of endogenous adenosine in chronic heart failure (CHF) are not fully understood. We analyzed the gene expression patterns of adenosine-related genes in human failing and nonfailing myocardium using DNA microarray analysis and quantitative real time-polymerase chain reaction (RT-PCR). DNA microarray analysis revealed that the gene expression of adenosine A2a, A2b, and A3 receptors (A2aR, A2bR, and A3R) as well as that of adenosine deaminase (ADA) decreased in failing myocardium. The down-regulation of these genes was verified by quantitative RT-PCR. We also measured the activities of these adenosine metabolism-related enzymes in failing myocardium and cardiac adenosine levels in patients with CHF. In CHF patients, we observed the decreased enzyme activity of ADA and the elevation of cardiac adenosine levels in CHF patients. To enhance the signaling of adenosine receptors, we increased plasma adenosine levels using dipyridamole, which decreased the severity of CHF. The gene expression of A2aR, A2bR, A3R, and ADA was decreased in the failing hearts, and this decrease may impair adenosine-related signal transduction. The activities of adenosine-related enzymes were altered, thus increasing the myocardial adenosine levels; this increase may compensate for the impairment of adenosine-related signal transduction in patients with CHF. The impairment of adenosine-related signal transmission contributes to the pathophysiology of CHF.
Collapse
Affiliation(s)
- Masanori Asakura
- Cardiovascular Division of Internal Medicine, National Cardiovascular Center, Suita, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Seguchi O, Takashima S, Yamazaki S, Asakura M, Asano Y, Shintani Y, Wakeno M, Minamino T, Kondo H, Furukawa H, Nakamaru K, Naito A, Takahashi T, Ohtsuka T, Kawakami K, Isomura T, Kitamura S, Tomoike H, Mochizuki N, Kitakaze M. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J Clin Invest 2007; 117:2812-24. [PMID: 17885681 PMCID: PMC1978424 DOI: 10.1172/jci30804] [Citation(s) in RCA: 126] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2006] [Accepted: 06/26/2007] [Indexed: 02/04/2023] Open
Abstract
Marked sarcomere disorganization is a well-documented characteristic of cardiomyocytes in the failing human myocardium. Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MLC2v), which is involved in the development of human cardiomyopathy, is an important structural protein that affects physiologic cardiac sarcomere formation and heart development. Integrated cDNA expression analysis of failing human myocardia uncovered a novel protein kinase, cardiac-specific myosin light chain kinase (cardiac-MLCK), which acts on MLC2v. Expression levels of cardiac-MLCK were well correlated with the pulmonary arterial pressure of patients with heart failure. In cultured cardiomyocytes, knockdown of cardiac-MLCK by specific siRNAs decreased MLC2v phosphorylation and impaired epinephrine-induced activation of sarcomere reassembly. To further clarify the physiologic roles of cardiac-MLCK in vivo, we cloned the zebrafish ortholog z-cardiac-MLCK. Knockdown of z-cardiac-MLCK expression using morpholino antisense oligonucleotides resulted in dilated cardiac ventricles and immature sarcomere structures. These results suggest a significant role for cardiac-MLCK in cardiogenesis.
Collapse
Affiliation(s)
- Osamu Seguchi
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Seiji Takashima
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Satoru Yamazaki
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Masanori Asakura
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Yoshihiro Asano
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Yasunori Shintani
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Masakatsu Wakeno
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Tetsuo Minamino
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Hiroya Kondo
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Hidehiko Furukawa
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Kenji Nakamaru
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Asuka Naito
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Tomoko Takahashi
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Toshiaki Ohtsuka
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Koichi Kawakami
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Tadashi Isomura
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Soichiro Kitamura
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Hitonobu Tomoike
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Naoki Mochizuki
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Masafumi Kitakaze
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| |
Collapse
|
16
|
Okazawa A, Kanai T, Nakamaru K, Sato T, Inoue N, Ogata H, Iwao Y, Ikeda M, Kawamura T, Makita S, Uraushihara K, Okamoto R, Yamazaki M, Kurimoto M, Ishii H, Watanabe M, Hibi T. Human intestinal epithelial cell-derived interleukin (IL)-18, along with IL-2, IL-7 and IL-15, is a potent synergistic factor for the proliferation of intraepithelial lymphocytes. Clin Exp Immunol 2004; 136:269-76. [PMID: 15086390 PMCID: PMC1809038 DOI: 10.1111/j.1365-2249.2004.02431.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Intestinal epithelial cell (IEC)-derived cytokines, such as stem cell factor (SCF), interleukin (IL)-7 and IL-15 are known to be required for the development of intestinal intraepithelial lymphocytes (IELs). A newly described cytokine, IL-18, has also been shown to be produced by intestinal epithelial cells. To demonstrate the functional effects of IL-18 on human IELs, we assessed IL-18/IL-18 receptor expression in IEC/IEL and proliferation following stimulation of intestinal IELs by IL-18. IL-18 transcripts were detected both in freshly isolated human colonic epithelial cells and in various colonic epithelial cell lines. IL-18 protein was also detected by ELISA and flow cytometric analysis using antihuman IL-18-specific monoclonal antibody (MoAb). Furthermore, IELs constitutively expressed the IL-18 receptor in addition to the IL-2 and IL-7 receptors. More importantly, IL-18 augmented significant proliferative responses of IEL in combination with IL-2, IL-7 and IL-15 both in the presence and in absence of anti-CD3 MoAb. These results suggest that IL-18 might play a crucial role in the proliferation and maintenance of intestinal IELs.
Collapse
Affiliation(s)
- A Okazawa
- Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Furukawa Y, Nakamaru K, Sasaki K, Fujisawa Y, Minakata H, Ohta S, Morishita F, Matsushima O, Li L, Alexeeva V, Ellis TA, Dembrow NC, Jing J, Sweedler JV, Weiss KR, Vilim FS. PRQFVamide, a novel pentapeptide identified from the CNS and gut of Aplysia. J Neurophysiol 2003; 89:3114-27. [PMID: 12612009 DOI: 10.1152/jn.00014.2003] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We have purified a novel pentapeptide from the Aplysia nervous system using bioassay on gut contractions. The structure of the peptide is Pro-Arg-Gln-Phe-Val-amide (PRQFVa). The precursor for PRQFVa was found to code for 33 copies of PRQFVamide and four related pentapeptides. Peaks corresponding to the predicted masses of all five pentapeptides were detected in Aplysia neurons by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Northern analysis revealed that expression of the precursor is abundant in the abdominal ganglion, much less in the pedal and cerebral ganglia, and rarely seen in the buccal and pleural ganglia. PRQFVa-positive neurons, mapped by immunohistochemistry and in situ hybridization, were present in all the central ganglia. PRQFVa immunopositive processes were observed in the gut, particularly in association with the vasculature. Some arteries and other highly vascularized tissues, such as the gill and the kidney, also contain numerous PRQFVa immunopositive processes. Application of synthetic PRQFVa suppresses not only contractions of the gut but also contractions of vasculature. PRQFVa is expressed in some of the neurons within the feeding circuitry and application of synthetic PRQFVa was found to decrease the excitability of some (B4/5 and B31/32) but not all (B8) neurons of the buccal feeding circuit. Our findings suggest that PRQFVa may act as a modulator within the feeding system as well as in other systems of Aplysia.
Collapse
Affiliation(s)
- Y Furukawa
- Graduate School of Science, Department of Biological Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Osawa H, Ochi M, Nishimiya T, Onuma H, Nakamaru K, Murakami A, Kato K, Shimizu I, Fujii Y, Ohashi J, Makino H. A systematic search for single nucleotide polymorphisms (SNPs) in the insulin receptor gene: association of an SNP with hyperlipidemia in Japanese type 2 diabetic subjects. Clin Genet 2001; 60:479-81. [PMID: 11846745 DOI: 10.1034/j.1399-0004.2001.600615.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
19
|
Furukawa Y, Nakamaru K, Wakayama H, Fujisawa Y, Minakata H, Ohta S, Morishita F, Matsushima O, Li L, Romanova E, Sweedler JV, Park JH, Romero A, Cropper EC, Dembrow NC, Jing J, Weiss KR, Vilim FS. The enterins: a novel family of neuropeptides isolated from the enteric nervous system and CNS of Aplysia. J Neurosci 2001; 21:8247-61. [PMID: 11588196 PMCID: PMC6763844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Abstract
To identify neuropeptides that have a broad spectrum of actions on the feeding system of Aplysia, we searched for bioactive peptides that are present in both the gut and the CNS. We identified a family of structurally related nonapeptides and decapeptides (enterins) that are present in the gut and CNS of Aplysia, and most of which share the HSFVamide sequence at the C terminus. The structure of the enterin precursor deduced from cDNA cloning predicts 35 copies of 20 different enterins. Northern analysis, in situ hybridization, and immunocytochemistry show that the enterins are abundantly present in the CNS and the gut of Aplysia. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry we characterized the enterin-precursor processing, demonstrated that all of the precursor-predicted enterins are present, and determined post-translational modifications of various enterins. Enterin-positive neuronal somata and processes were found in the gut, and enterins inhibited contractions of the gut. In the CNS, the cerebral and buccal ganglia, which control feeding, contained the enterins. Enterin was also present in the nerve that connects these two ganglia. Enterins reduced the firing of interneurons B4/5 during feeding motor programs. Such enterin-induced reduction of firing also occurred when excitability of B4/5 was tested directly. Because reduction of B4/5 activity corresponds to a switch from egestive to ingestive behaviors, enterin may contribute to such program switching. Furthermore, because enterins are present throughout the nervous system, they may also play a regulatory role in nonfeeding behaviors of Aplysia.
Collapse
Affiliation(s)
- Y Furukawa
- Department of Biological Science, Faculty of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Kanai T, Watanabe M, Okazawa A, Nakamaru K, Okamoto M, Naganuma M, Ishii H, Ikeda M, Kurimoto M, Hibi T. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. Gastroenterology 2000; 119:1514-23. [PMID: 11113073 DOI: 10.1053/gast.2000.20260] [Citation(s) in RCA: 97] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND & AIMS Crohn's disease (CD) is characterized by a marked accumulation of activated Th1 type CD4(+) T cells and macrophages in inflamed intestinal mucosa. Interleukin (IL)-18 is a recently described cytokine that mainly exists in activated macrophages and shares biological activities with IL-12 in driving the development of Th1 type CD4(+) T cells by inducing interferon gamma. To clarify the role of IL-18 in intestinal inflammation in CD, we assessed the functional role of IL-18 in regulating intestinal mucosal lymphocytes. METHODS Serum IL-18 concentration was measured by enzyme-linked immunosorbent assay. Expression of IL-18 and IL-18 receptor in human intestinal mucosa was determined using immunohistochemistry and flow cytometry. The functional activity of IL-18 was assessed by the use of recombinant IL-18 to stimulate both the growth of intestinal mucosal lymphocytes and IL-2 receptor induction activity. RESULTS The serum IL-18 concentration was significantly higher in patients with CD than normal controls. In the inflamed colonic mucosa of CD, many IL-18(+)CD68(+) macrophages had infiltrated the lamina propria. Intestinal mucosal lymphocytes from CD expressed functional IL-18 receptors. Recombinant IL-18 induced significant proliferative responses in freshly isolated mucosal lymphocytes from CD patients, but not from normal controls. IL-18 up-regulated IL-2 receptor expression in mucosal lymphocytes from patients with CD, but not from normal controls. CONCLUSIONS These findings suggest that infiltrated macrophages in the inflamed intestinal mucosa in CD produce IL-18, and that macrophage-derived IL-18 may serve as a potent regulatory factor for intestinal mucosal lymphocytes, thereby contributing to chronic intestinal inflammation in CD.
Collapse
Affiliation(s)
- T Kanai
- Keio Cancer Center, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Nakajima T, Nakamaru K, Ido E, Terao K, Hayami M, Hasegawa M. Development of novel simian immunodeficiency virus vectors carrying a dual gene expression system. Hum Gene Ther 2000; 11:1863-74. [PMID: 10986559 DOI: 10.1089/10430340050129486] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The development of highly efficient and safe gene transfer methods suitable for clinical use is required for human gene therapies. We have developed a novel lentiviral vector system, based on the nonpathogenic simian immunodeficiency virus from African green monkeys (SIVagm), that carries a unique dual gene expression system. This system utilizes the lentivirus Rev responsive element (RRE). Self-inactivating vectors were also developed by deleting a U3 region in the 3' long terminal repeat (3' LTR) of the virus. When pseudotyped with a vesicular stomatitis virus envelope glycoprotein G (VSV-G), the SIVagm-based vectors could transduce both growth-arrested human cells and terminally differentiated neuronal cell lines. Using these vectors, two reporter genes could be expressed simultaneously at equal levels, and expression levels of both genes could be altered by modifying the length of the RRE sequence. These SIVagm-based vectors might offer safety advantages over other lentivirus-based vectors. Furthermore, the novel dual gene expression system described here could increase the usefulness and value of both viral and nonviral vectors in gene therapy.
Collapse
Affiliation(s)
- T Nakajima
- DNAVEC Research, Inc., Tsukuba, Ibaraki 305-0856, Japan
| | | | | | | | | | | |
Collapse
|
22
|
Fujisawa Y, Furukawa Y, Ohta S, Ellis TA, Dembrow NC, Li L, Floyd PD, Sweedler JV, Minakata H, Nakamaru K, Morishita F, Matsushima O, Weiss KR, Vilim FS. The Aplysia mytilus inhibitory peptide-related peptides: identification, cloning, processing, distribution, and action. J Neurosci 1999; 19:9618-34. [PMID: 10531464 PMCID: PMC6782896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/1999] [Revised: 08/16/1999] [Accepted: 08/16/1999] [Indexed: 02/14/2023] Open
Abstract
Neuropeptides are a ubiquitous class of signaling molecules. In our attempt to understand the generation of feeding behavior in Aplysia, we have sought to identify and fully characterize the neuropeptides operating in this system. Preliminary evidence indicated that Mytilus inhibitory peptide (MIP)-like peptides are present and operating in the circuitry that generates feeding in Aplysia. MIPs were originally isolated from the bivalve mollusc Mytilus edulis, and related peptides have been identified in other invertebrate species, but no precursor has been identified. In this study, we describe the isolation and characterization of novel Aplysia MIP-related peptides (AMRPs) and their precursor. Several AMRPs appear to have some structural and functional features similar to vertebrate opioid peptides. We use matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to confirm that all 14 AMRPs predicted by the precursor are processed in isolated neurons. Northern analysis, whole-mount in situ hybridization, and immunohistochemistry are used to map the abundant expression of these peptides in the CNS and peripheral tissues such as the digestive tract, vasculature, and the reproductive organs. Physiological studies demonstrate that the rank order of the inhibitory actions of these peptides is different for three target muscles. These results underscore the importance of using a multidisciplinary approach to identifying and characterizing the actions of neuropeptides in an effort to gain understanding of their role in systems of interest. The widespread distribution of the AMRPs indicates that they may be operating in many different systems of Aplysia.
Collapse
Affiliation(s)
- Y Fujisawa
- Suntory Institute for Bioorganic Research, Shimamoto, Mishima, Osaka 618-8503, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Furukawa Y, Fujisawa Y, Minakata H, Nakamaru K, Wakayama H, Nakabayashi K, Morishita F, Matsushima O, Ellis TA, Dembrow NC, Weiss KR, Vilim FS. The Enterins: A novel family of neuropeptides isolated from the enteric and central nervous system of Aplysia. Comp Biochem Physiol A Mol Integr Physiol 1999. [DOI: 10.1016/s1095-6433(99)90055-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Akari H, Yagita H, Nishida T, Nakamaru K, Terao K, Yoshikawa Y, Adachi A. Selective expression of beta 7 integrin on lymphocytes undergoing apoptosis in lymphoid tissues. Biochem Biophys Res Commun 1998; 244:578-82. [PMID: 9514955 DOI: 10.1006/bbrc.1998.8308] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
It has been previously shown that the beta 7 chain of integrin forms heterodimers with the alpha 4 or alpha E chain, which plays essential roles in lymphocyte homing to mucosal lymphoid tissues. The aim of this study was to re-evaluate the possible role of the beta 7 integrin other than lymphocyte homing. We prepared spleen and lymph node lymphocytes from biopsied specimens from macaque monkeys and examined for the reactivity with a monoclonal antibody specific for the beta 7 chain. As a result, a minor population of the lymphocytes with a smaller size, which were in the early stage of apoptosis, was found to express a higher level of the beta 7 integrin than a majority of the lymphocytes with a normal size. Interestingly, the apoptotic lymphocytes expressed neither alpha 4 nor alpha E chains, suggesting that the beta 7 chain on these cells may be associated with an undefined alpha chain. These findings indicate that in the lymphoid tissues the shrunken lymphocytes undergoing apoptosis selectively express a unique beta 7 integrin.
Collapse
Affiliation(s)
- H Akari
- Department of Virology, School of Medicine, University of Tokushima, Japan.
| | | | | | | | | | | | | |
Collapse
|
25
|
Sasaki R, Hirota K, Nakamaru K, Masuda A, Satone T, Ito Y. [Influence of fluid replacement on serum magnesium concentration and proper magnesium supplementation during general anesthesia]. Masui 1997; 46:1179-85. [PMID: 9311207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We have studied the influence of fluid replacement on serum magnesium (Mg2+) concentrations, and studied proper Mg2+ supplementation during general anesthesia. Thirty eight patients undergoing elective surgery randomly received: Mg(2+)-free acetated Ringer solution (Group I, n = 15), acetated Ringer solution containing 0.5 mmol.l-1 of Mg2+ (Group II, n = 6), 1.0 mmol.l-1 of Mg2+ (Group III, n = 7), 2.0 mmol.l-1 of Mg2+ (Group IV, n = 6), or 4.0 mmol.l-1 of Mg2+ (Group V, n = 4). Measurements were made on serum and urine Mg2+ concentrations during anesthesia. In Group I, the serum Mg2+ concentrations decreased in correspondence with the water balance. It is suggested that dilution due to the fluid replacement induced the reduction in serum Mg2+ concentrations since the observed urine Mg2+ concentrations were negligible. In Group II-V, the reduction in serum Mg2+ concentrations was inhibited by Mg2+ supplementation, and the serum Mg2+ concentrations remained unchanged in Group IV. We conclude the Mg2+ supplementation is required during anesthesia when a large amount of fluid is infused.
Collapse
Affiliation(s)
- R Sasaki
- Department of Anesthesiology, Toyama Medical and Pharmaceutical University School of Medicine
| | | | | | | | | | | |
Collapse
|
26
|
Abstract
We compared the effect of propofol with that of sevoflurane anesthesia on uric acid (UA) excretion in ASA physical status I and II patients with normal renal function. A propofol group (n = 11) received propofol-nitrous oxide-fentanyl after induction of anesthesia by propofol, while a sevoflurane group (n = 12) received sevoflurane-nitrous oxide-fentanyl after induction of anesthesia by thiamylal. UA, creatinine (Cr), and urea nitrogen concentrations in serum and urine were measured before induction of anesthesia, 1, 2, and 3 h after induction, and on Postoperative Day 1. N-acetyl-beta-D-glucosaminidase, beta2-microglobulin concentrations, and pH in urine were also examined. Plasma clearance of UA (CUA) and Cr (CCr) were calculated. The hourly concentration and excretion of urine UA were significantly higher than those of the sevoflurane group (P < 0.01). Significant correlations were noted between the hourly urine volume and UA concentration (r = 0.58, P < 0.01 for the propofol group; r = 0.51, P < 0.01 for the sevoflurane group). The CUA of the propofol group was significantly higher than that of the sevoflurane group (22.9 +/- 10.6 vs 5.9 +/- 3.4 mL/min, mean +/- SD, P < 0.05). There were no significant differences in other renal variables between the two groups. The present study demonstrated that the UA excretion increased during propofol anesthesia, while it remained stable during sevoflurane anesthesia.
Collapse
Affiliation(s)
- A Masuda
- Department of Anesthesiology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani, Japan.
| | | | | | | | | | | |
Collapse
|
27
|
Hamada T, Yamamoto M, Nakamaru K, Iwaki K, Ito Y, Koizumi T. [The pharmacokinetics of D-lactate, L-lactate and acetate in humans]. Masui 1997; 46:229-36. [PMID: 9071107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
In this study, the pharmacokinetics of D-lactate, L-lactate and acetate were investigated in 36 adult surgical patients. After induction of general anaesthesia, the subjects received intravenous injection of either 5 mmoles of D-lactate and 5 mmoles of L-lactate simultaneously (Group DL), 10 mmoles of L-lactate (Group L), or 10 mmoles of acetate (Group A). Serial arterial blood samples were obtained before the injection, and 3, 5, 7, 9 and 11 minutes after the infusion of each preparation. Plasma concentrations of D-lactate, L-lactate and acetate were measured by high performance liquid chromatography, enzymatic analysis and spectrophotometry. The pharmacokinetic parameters; distribution volume (Vd) and half-life (t1/2) were calculated with a one-compartment model from the incremental plasma concentration decay curve after administration. In Group DL, there were no differences between D-lactate and L-lactate in Vd and t1/2. Also, between L-lactate in Group DL and that in Group L, there were no differences in Vd and t1/2. The Vd and T1/2 of acetate, however, were smaller than those of L-lactate in Group L. We conclude that the pharmacokinetics of D-lactate is similar to those of L-lactate, and that acetate may be metabolized more rapidly than L-lactate.
Collapse
Affiliation(s)
- T Hamada
- Department of Anesthesiology, Faculty of Medicine, Toyama Medical and Pharmaceutical University
| | | | | | | | | | | |
Collapse
|
28
|
Nakamaru K, Sugai T, Kinoshita N, Sato M, Taniguchi S, Kawase S. [Effect of mesalazine, an agent for the treatment of idiopathic inflammatory bowel disease, on reactive oxygen metabolites and LTB4 formation]. Nihon Yakurigaku Zasshi 1994; 104:447-57. [PMID: 7851818 DOI: 10.1254/fpj.104.447] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Mesalazine microgranules (Pentasa) were developed as a drug for idiopathic inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. In this study, we examined the effect of mesalazine on radical scavenging, lipid peroxidation and the formation of LTB4. Mesalazine reduced the free radical 1,1-diphenyl-2-picrylhydrazyl with an IC50 value of 9.5 microM. It scavenged hydrogen peroxide and hypochlorite (IC50: 0.7 microM and 37.0 microM, respectively), but had no effect on superoxide. Lipid peroxidation in rat liver microsomes was inhibited by mesalazine (IC50: 12.6 microM). Mesalazine significantly inhibited (P < 0.01) gastric mucosal lipid peroxidation induced by ischemia and reperfusion in rats at a dose of 50 mg/kg, p.o. Mesalazine also inhibited the formation of LTB4 in rat peritoneal neutrophils (IC50: 44.9 microM). N-Acetyl-mesalazine, the metabolite of mesalazine, had no effect on radical scavenging and lipid peroxidation. Only a high concentration (1 mM) of the metabolite inhibited the formation of LTB4. These studies suggest that mesalazine inhibits cell injury in the inflamed mucosa by scavenging reactive oxygen metabolites and prevents the invasion of neutrophils by inhibition of LTB4 formation.
Collapse
Affiliation(s)
- K Nakamaru
- Pharmaceutical Research Center, Nisshin Flour Milling Co., Ltd., Saitama, Japan
| | | | | | | | | | | |
Collapse
|
29
|
Nakamaru K, Sugai T, Hongyo T, Sato M, Taniguchi S, Tanaka Y, Kawase S. [Effect of mesalazine microgranules on experimental colitis]. Nihon Yakurigaku Zasshi 1994; 104:303-11. [PMID: 7959421 DOI: 10.1254/fpj.104.303] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Mesalazine microgranules are an ethylcellulose-coated formulation from which mesalazine is released throughout the intestinal tract and are expected to be effective for idiopathic inflammatory bowel disease, ulcerative colitis and Crohn's disease. Mesalazine microgranules were administered orally to investigate the distribution of mesalazine throughout the intestinal tract in rats. Mesalazine microgranules distributed sufficient amounts of mesalazine and its metabolite, N-acetyl-mesalazine, to the intestinal tissues, while pure mesalazine delivered lower amounts of both. In acetic acid-induced colitis in rats, mesalazine microgranules administered orally reduced the damage score significantly (P < 0.05) at a dose of 50 mg/kg as assessed by macroscopic observation and at 100 mg/kg as assessed by histological evaluation. The number of ulcers in carrageenan-induced colitis in guinea pigs was inhibited at doses of 50, 100, 200 mg/kg, p.o. The colonic wet weight of rats in 2,4,6-trinitrobenzenesulfonic acid (TNB)-induced colitis was reduced significantly (P < 0.05) at a dose of 50 mg/kg, p.o. Mesalazine microgranules showed the ability to distribute mesalazine efficiently throughout the intestinal tract and showed effectiveness against acetic acid-, carrageenan- and TNB-induced colitis. These studies strongly suggest that mesalazine microgranules are effective for idiopathic inflammatory bowel disease.
Collapse
Affiliation(s)
- K Nakamaru
- Pharmaceutical Research Center, Nisshin Flour Milling Co., Ltd., Saitama, Japan
| | | | | | | | | | | | | |
Collapse
|
30
|
Kuze S, Naruse T, Ito Y, Nakamaru K. Comparative study of intravenous administration of Ringer’s lactate, Ringer’s acetate and 5% glucose containing these Ringer’s solutions in human being. J Anesth 1990; 4:155-61. [PMID: 15236001 DOI: 10.1007/s0054000040155] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/1988] [Accepted: 11/07/1989] [Indexed: 10/26/2022]
Abstract
The effects of the administration of Ringer's lactate (L) and Ringer's acetate (A) solution on blood biochemistry in human subjects operated for tympanoplasty under general anesthesia were investigated. And the feasibilities of the clinical use of Ringer's lactate (LD) and Ringer's acetate (AD) solution containing 5% glucose were also assessed. In all cases the rate of infusion was 500 ml for initial 20 min, and then 5 ml.hr(-1).kg(-1) B.W. for 3 hr and 10 min. There were significant increases in blood L- and D-lactate, pyruvate, and L-lactate/pyruvate ratio in L group. A significant increase in blood acetate but not lactate was found in A group. These metabolic changes were minimal and considered as clinically not significant. The urinary excretion of lactate, pyruvate, acetate and glucose were also negligible. In both LD and AD group, the higher blood concentrations of lactate, pyruvate, acetate and glucose were found than in L and A group. Urinary excretions of these metabolites were much higher in LD and AD group than in L and A group. So glucose containing Ringer's lactate or acetate solutions should be administered in appropriate amounts and rate not to induce clinically significant metabolic alterations.
Collapse
Affiliation(s)
- S Kuze
- Department of Anesthesiology, Toyama Medical and Pharmaceutical University, Toyama, Japan
| | | | | | | |
Collapse
|
31
|
Yano S, Harada M, Watanabe K, Nakamaru K, Hatakeyama Y, Shibata S, Takahashi K, Mori T, Hirabayashi K, Takeda M. Antiulcer activities of glycyrrhetinic acid derivatives in experimental gastric lesion models. Chem Pharm Bull (Tokyo) 1989; 37:2500-4. [PMID: 2605700 DOI: 10.1248/cpb.37.2500] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Glycyrrhetinic acid (Ia) and eighteen related derivatives were examined for antiulcer activity using stress-induced gastric lesions (restraint plus water immersion at 25 degrees C) in mice and rats as screening tests. Among the compounds tested, dihemiphthalate derivatives of 18 alpha- or 18 beta-olean-12-ene-3 beta,30-diol (IV, IIId), 18 beta-olean-9(11)12-diene-3 beta,30-diol (VIc), and olean-11,13(18)-diene-3 beta,30-diol (VIIc) showed potent inhibition of gastric lesion formation at a dose of 12 or 25 mg/kg (p.o.); carbenoxolone sodium (Ib) significantly suppressed the lesion formation at a dose of 500 mg/kg (p.o.). Further evaluation of the antiulcer activity was carried out mainly for compound IIId. Compound IIId (p.o.) prevented the formation of indomethacin-induced or 0.6 N HCl-induced gastric lesions; the latter antiulcer effect was noted even in the combined treatment with indomethacin, suggesting that the effect occurs independently of endogenous prostaglandins. In contrast, compound IIId had no preventive effect against Shay rat ulcer when intragastrically (i.g.) administered; further, no antisecretory effect was seen by i.g. application in pylorus-ligated rats. Administration of compound IIId for 2 weeks accelerated the healing rate of acetic acid-induced gastric ulcer in rats. No significant change in urine excretion was observed after its consecutive administration for 3 d. These results suggest that dihemiphthalate derivatives (IIId, IV, VIc, VIIc) may produce a strong antiulcer activity, probably by strengthening some gastric mucosal defensive mechanism.
Collapse
|
32
|
Suzuki S, Nakamaru K, Suzuki M, Asami A, Kanayama M. [Measurement of plasma fibronectin by laser nephelometry]. Rinsho Byori 1983; 31:1239-1243. [PMID: 6672297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
33
|
|